Coadministration studied
BPC-157 + TB-500 / thymosin beta-4
Has this popular “recovery stack” actually been studied in people?
Barely. One retrospective knee-pain report included four people who received BPC-157 plus thymosin beta-4. It had no randomization, control group, or blinding, and it cannot establish combination safety, effectiveness, or broad injury repair.
Direct evidence: Four-person uncontrolled retrospective subset
Interaction boundary: Combination safety, effectiveness, and broad injury repair are not established.
The catch: “TB-500” may not identify the same material as full thymosin beta-4. Evidence for one cannot automatically be transferred to the other.
No adequate direct evidence
CJC-1295 + ipamorelin
Does the combination have human evidence for muscle gain, recovery, or better sleep?
PepCurrent’s July 18 search did not identify an adequate human trial of the combination establishing those outcomes. Human CJC-1295 work measured growth hormone and IGF-1; that is not the same as proving muscle gain, recovery, or sleep benefit.
Direct evidence: No adequate direct human combination trial identified for the claimed outcomes
Interaction boundary: Human combination effects and risks remain inadequately characterized.
The catch: The often-cited ipamorelin selectivity study was conducted in animals. Human combination effects and risks remain inadequately characterized.
Known label boundary
Semaglutide + tirzepatide
Do the approved labels support taking these together?
No. Wegovy labeling says use with another GLP-1 receptor agonist is not recommended. Zepbound labeling likewise says coadministration with another GLP-1 receptor agonist is not recommended.
Direct evidence: FDA-approved labeling addresses coadministration with another GLP-1 receptor agonist
Interaction boundary: Coadministration is not recommended in the cited approved labels; this is not individualized medical advice.
The catch: This is a label-level boundary, not an individualized instruction. It does not establish the contents or identity of products sold outside the approved supply chain.
Coadministration studied
Cagrilintide + semaglutide (CagriSema)
Is this a real studied combination, or just an internet stack?
Defined cagrilintide and semaglutide study products were coadministered in human trials. REDEFINE 1 used a double-dummy, two-injection design. Those results do not validate unrelated mixing, online products, or a do-it-yourself version.
Direct evidence: Direct Phase 3 evidence for coadministration of defined sponsor study products
Interaction boundary: Coadministration evidence for defined sponsor study products does not establish the safety, compatibility, identity, or performance of unrelated mixing or products.
The catch: The proposed NDA product is a sponsor-defined fixed-dose combination; the published trials coadministered defined sponsor study products. Submission is not approval, and neither record authenticates an unrelated product.
No adequate direct evidence
BPC-157 + GHK-Cu
Does the “Glow” pairing have direct human combination evidence?
PepCurrent’s July 18 search did not identify adequate direct human evidence for the combination. Separate laboratory or preclinical findings for each ingredient do not establish what happens when they are combined.
Direct evidence: No adequate direct human evidence identified for the combination
Interaction boundary: Chemical compatibility, stability, sterility, safety, and clinical effect are not established.
The catch: A blend name is marketing shorthand, not proof of chemical compatibility, sterility, stability, safety, or a clinical effect.
Registry structured 2026-07-26 from checks independently reviewed 2026-07-18. These are dated evidence checks, not an exhaustive assurance that no other study exists.